Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03206645 · ClinicalTrials.gov registry record · Phase 1
Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
A Phase 1 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03206645 is a Phase 1 study that has completed, run by University of Oklahoma. The registered enrollment target is 27 participants.
The verdict
NCT03206645, a Phase 1 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is previously untreated.
Interventions
- DRUG Unesbulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03206645
The ClinicalTrials.gov registry entry for NCT03206645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Unesbulin is the first listed.
NCT03206645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03206645 about?
NCT03206645 is a clinical study titled "Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy". This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of Unesbulin when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ...
What is the current status of trial NCT03206645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2017-08-28. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT03206645?
The interventions under investigation include: Unesbulin (DRUG).
Who is sponsoring clinical trial NCT03206645?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.